MaxCyte, Inc. Depreciation and Amortization
MaxCyte, Inc. (MXCT) reported Depreciation and Amortization of $2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-13
- MaxCyte, Inc. depreciation, depletion and amortization for the quarter ending 2026-06-30 was $978.00K, a 11.09% decline year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization for the quarter ending 2026-03-31 was $1.05M, a 4.47% decline year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization for the quarter ending 2025-12-31 was $1.07M, a 1.42% increase year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization for the quarter ending 2025-09-30 was $1.07M, a 0.56% increase year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization for fiscal 2025 was $4.34M, a 0.58% increase from fiscal 2024.
- MaxCyte, Inc. depreciation, depletion and amortization for fiscal 2024 was $4.32M, a 3.45% increase from fiscal 2023.
- MaxCyte, Inc. depreciation, depletion and amortization for fiscal 2023 was $4.17M, a 54.60% increase from fiscal 2022.
- MaxCyte, Inc. depreciation, depletion and amortization for fiscal 2022 was $2.70M, a 89.48% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 3 month as first filed | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 6 month as first filed | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 9 month as first filed | Depreciation, Depletion and Amortization 12 month | Depreciation, Depletion and Amortization 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $978.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.02M 10-Q · filed 2026-08-13 | $3.10M derived: sum of 3 quarters · filed 2026-08-13 | $4.17M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.05M 10-Q · filed 2026-05-13 | $2.12M derived: sum of 2 quarters · filed 2026-05-13 | $3.19M derived: sum of 3 quarters · filed 2026-05-13 | $4.29M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.14M derived: sum of 2 quarters · filed 2026-03-25 | $3.24M derived: sum of 3 quarters · filed 2026-08-13 | $4.34M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.17M derived: sum of 2 quarters · filed 2026-08-13 | $3.27M 10-Q · filed 2025-11-13 | $4.33M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.20M 10-Q · filed 2026-08-13 | $3.25M derived: sum of 3 quarters · filed 2026-08-13 | $4.32M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-13 | $2.15M derived: sum of 2 quarters · filed 2026-05-13 | $3.22M derived: sum of 3 quarters · filed 2026-05-13 | $4.30M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.12M derived: sum of 2 quarters · filed 2026-03-25 | $3.20M derived: sum of 3 quarters · filed 2026-03-25 | $4.32M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $1.07M 10-Q · filed 2024-11-06 | $2.15M derived: sum of 2 quarters · filed 2024-11-06 | $3.26M 10-Q · filed 2025-11-13 | $4.36M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2024-06-30 | $1.08M 10-Q · filed 2024-08-06 | $2.19M 10-Q · filed 2025-08-06 | $3.29M derived: sum of 3 quarters · filed 2025-05-08 | $4.38M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2024-03-31 | $1.11M 10-Q · filed 2025-05-08 | $2.21M derived: sum of 2 quarters · filed 2025-05-08 | $3.29M derived: sum of 3 quarters · filed 2025-05-08 | $4.32M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.18M derived: sum of 2 quarters · filed 2025-03-11 | $3.21M derived: sum of 3 quarters · filed 2025-03-11 | $4.17M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $1.08M 10-Q · filed 2024-11-06 | $1.08M 10-Q · filed 2023-11-08 | $2.11M derived: sum of 2 quarters · filed 2024-11-06 | $3.07M 10-Q · filed 2024-11-06 | $3.07M 10-Q · filed 2023-11-08 | $3.99M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $1.03M 10-Q · filed 2024-08-06 | $1.03M 10-Q · filed 2023-08-09 | $1.99M 10-Q · filed 2024-08-06 | $1.99M 10-Q · filed 2023-08-09 | $2.91M derived: sum of 3 quarters · filed 2024-08-06 | $3.65M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $962.00K 10-Q · filed 2024-05-07 | $961.70K 10-Q · filed 2023-05-10 | $1.88M derived: sum of 2 quarters · filed 2024-05-07 | $2.63M derived: sum of 3 quarters · filed 2024-05-07 | $3.17M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $919.70K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.66M derived: sum of 2 quarters · filed 2024-03-12 | $2.21M derived: sum of 3 quarters · filed 2024-03-12 | $2.70M 10-K · filed 2024-03-12 | $2.70M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $743.30K 10-Q · filed 2023-11-08 | $1.29M derived: sum of 2 quarters · filed 2023-11-08 | $1.78M 10-Q · filed 2023-11-08 | $2.19M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $547.40K 10-Q · filed 2023-08-09 | $1.03M 10-Q · filed 2023-08-09 | $1.45M derived: sum of 3 quarters · filed 2023-08-09 | $1.82M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $487.40K 10-Q · filed 2023-05-10 | $903.90K derived: sum of 2 quarters · filed 2023-05-10 | $1.27M derived: sum of 3 quarters · filed 2023-05-10 | $1.59M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $416.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $782.50K derived: sum of 2 quarters · filed 2023-03-15 | $1.11M derived: sum of 3 quarters · filed 2023-03-15 | $1.42M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $366.00K 10-Q · filed 2022-11-09 | $691.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.01M 10-Q · filed 2022-11-09 | |||||
| 2021-06-30 | $325.00K 10-Q · filed 2022-08-10 | $641.40K 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | $315.90K 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $1.05M 10-K · filed 2022-03-22 | |||||||
| 2019-12-31 | $613.50K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |